C6A60028-2402-4048-90DF-F2B3712FB530
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 24.375821287779235
- age_years
- 46
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.655
- INTERFERON_GAMMA_RESPONSE+0.594
- ANGIOGENESIS+0.525
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.524
- ALLOGRAFT_REJECTION+0.514
- IL6_JAK_STAT3_SIGNALING+0.506
- G2M_CHECKPOINT+0.479
- IL2_STAT5_SIGNALING+0.464
- APOPTOSIS+0.460
- TGF_BETA_SIGNALING+0.456
Top 10 suppressed
- KRAS_SIGNALING_DN-0.374
- SPERMATOGENESIS-0.321
- PANCREAS_BETA_CELLS-0.074
- OXIDATIVE_PHOSPHORYLATION+0.035
- HEDGEHOG_SIGNALING+0.075
- MYOGENESIS+0.090
- BILE_ACID_METABOLISM+0.094
- HEME_METABOLISM+0.101
- ESTROGEN_RESPONSE_EARLY+0.173
- UV_RESPONSE_UP+0.175
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DB34442C-1882-495A-A2F0-2427116A1FAF | — | — | 0.981 |
| 2 | C13F6AB6-41C0-4F51-A240-BA4F4410B68E | — | — | 0.973 |
| 3 | SRR934750 | — | — | 0.969 |
| 4 | E9FC1686-028B-476C-B51B-4956213D874B | — | — | 0.966 |
| 5 | 2DAB6792-F9AF-4565-BDD5-C9802F3132F4 | — | — | 0.962 |
| 6 | 59B8FDC4-299D-45B9-9AC1-526B7ED652CE | — | — | 0.961 |
| 7 | SRR934782 | — | — | 0.961 |
| 8 | DD203D19-D635-4112-AF75-9724E0A64A0B | — | — | 0.960 |
| 9 | 44B1F003-553A-4C8A-A6AE-44C49262081C | — | — | 0.959 |
| 10 | 113D7756-712E-4EB4-9993-BBAF3C41AFEF | — | — | 0.958 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 47 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.655 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.594 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.525 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.524 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.514 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.506 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.479 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.464 | Idelalisib | — uncovered |
| APOPTOSIS | 0.460 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.456 | Inavolisib | — uncovered |
| COMPLEMENT | 0.433 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.422 | Inavolisib | — uncovered |
| HYPOXIA | 0.420 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.397 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.393 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.393 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.373 | Idelalisib | — uncovered |
| COAGULATION | 0.357 | Binimetinib | — uncovered |
| GLYCOLYSIS | 0.357 | Inavolisib | — uncovered |